Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Consensus Rating of “Strong Buy” from Brokerages

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) have been assigned a consensus rating of “Strong Buy” from the seven research firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, one has given a buy rating and five have issued a strong buy rating on the company.

Several brokerages have recently issued reports on ZLDPF. Wells Fargo & Company upgraded shares of Zealand Pharma A/S to a “strong-buy” rating in a report on Thursday, July 24th. BNP Paribas upgraded shares of Zealand Pharma A/S to a “strong-buy” rating in a report on Tuesday, July 1st. Zacks Research upgraded shares of Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a report on Monday, September 15th. Finally, Barclays upgraded shares of Zealand Pharma A/S to a “strong-buy” rating in a report on Monday, July 7th.

Zealand Pharma A/S Stock Performance

Shares of OTCMKTS:ZLDPF opened at $77.42 on Thursday. Zealand Pharma A/S has a 52 week low of $49.98 and a 52 week high of $126.00. The company’s 50 day moving average is $67.30 and its two-hundred day moving average is $64.49. The company has a current ratio of 15.09, a quick ratio of 15.08 and a debt-to-equity ratio of 0.02. The company has a market cap of $5.50 billion, a PE ratio of 5.44 and a beta of 0.74.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last announced its quarterly earnings data on Thursday, August 14th. The company reported $16.06 EPS for the quarter, missing analysts’ consensus estimates of $16.72 by ($0.66). Zealand Pharma A/S had a net margin of 73.90% and a return on equity of 67.06%. The firm had revenue of $1.43 billion during the quarter, compared to analysts’ expectations of $9.18 billion. Equities analysts predict that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.